# Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

> **NCT01155713** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 63 (actual)

## Conditions studied

- Neoplasm
- Cancer
- Tumors

## Interventions

- **DRUG:** TKI258

## Key facts

- **NCT ID:** NCT01155713
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01155713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01155713, "Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT01155713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*